Darunavir vs Tipranavir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV protease · full HIV pipeline
Darunavir · Prezista
Marketed by Johnson & Johnson
NCT00110877 · Phase 3 · completed
The study randomly assigned 604 participants to darunavir/ritonavir or an active lopinavir/ritonavir comparator, but it was open-label rather than blinded. Its primary endpoint was a surrogate virologic measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: June 2027 · NCT06337032 (registry estimate)
Reported efficacy
Number of Participants with Viral load <400 copies/mL per TLOVR algorithm at Week 48 (Per Protocol Population) (48 weeks): HIV RNA <400 copies/mL at Week 48 (per-protocol population): darunavir-ritonavir 77% (220/286) vs lopinavir-ritonavir 68% (199/293); estimated difference 9% (95% CI 2-16). (met)
Result source: NCT00110877
Tipranavir · Aptivus
Marketed by Boehringer Ingelheim
NCT00144170 · Phase 3 · completed
The trial randomized participants to an active comparator and included 882 enrolled participants, with 863 in the reported efficacy denominators, but the registry does not clearly report masking. Both primary virologic endpoints favored tipranavir with statistically significant comparisons; however, the primary outcomes were virologic surrogate measures rather than hard clinical outcomes, so the evidence is rated moderate.
Reported efficacy
Treatment Response at Week 48 (after 48 weeks of treatment); Time to Treatment Failure Through 48 Weeks of Treatment (after 48 weeks of treatment): Treatment Response at Week 48 (after 48 weeks of treatment): Tipranavir(TPV)/Low Dose Ritonavir(r) 34.5% vs Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r) 15% (met)
Result source: NCT00144170
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Darunavir | Tipranavir |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not posted · NCT00110877 | —Not reported |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not posted · NCT00110877 | —Not reported |
| CD4 count, change (week 48) | 5 vs 41vs SBRNCT019685511 other result
| 43 vs 16vs Comparator Protease InhibitorNCT0014417019 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Darunavir
- —Not posted · NCT00110877
- Tipranavir
- —Not reported
HIV-1 RNA 50 copies/mL or more (week 48)
- Darunavir
- —Not posted · NCT00110877
- Tipranavir
- —Not reported
CD4 count, change (week 48)
- Darunavir
- 5 vs 41vs SBRNCT01968551
1 other result
- 23 vs 12 NCT01968551
- Tipranavir
- 43 vs 16vs Comparator Protease InhibitorNCT00144170
19 other results
- 46 vs 28 NCT00054717
- 47 vs 19 NCT00144170
- 39 vs 16 NCT00144170
- 50 vs 24 NCT00054717
- 52 vs 26 NCT00054717
- 46 vs 17 NCT00144170
- 42 vs 13 NCT00144170
- 51 vs 26 NCT00054717
- 50 vs 26 NCT00054717
- 51 vs 21 NCT00144170
- 42 vs 18 NCT00144170
- 54 vs 24 NCT00054717
- 50 vs 24 NCT00054717
- 39 vs 19 NCT00144170
- 55 vs 26 NCT00054717
- 41 vs 19 NCT00144170
- 60 vs 29 NCT00054717
- 41 vs 20 NCT00144170
- 60 vs 28 NCT00054717
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Darunavir: 4 of 4 rows · Tipranavir: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Darunavir | Tipranavir |
|---|---|---|
| Dropout rate | 10%a NCT01869634 · Phase 4 · registry result, not featured evidence show 34 more results—Darunavir/Ritonavir Alone NCT00630734 · Phase 4 · registry result, not featured evidence · monotherapy —Pravastatin + Darunavir/Ritonavir NCT00630734 · Phase 4 · registry result, not featured evidence · combination 0% NCT00543101 · Phase 4 · registry result, not featured evidence n/a: no completion milestoneContinued Treatment With DRV in Co NCT01281813 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneContinued Treatment With DRV in Co NCT01281813 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneContinued Treatment With DRV in Co NCT01281813 · Phase 3 · registry result, not featured evidence · combination —D/C/F/TAF: Extension Study NCT03227861 · Phase 3 · registry result, not featured evidence —D/C/F/TAF: Main Study NCT03227861 · Phase 3 · registry result, not featured evidence 9.1%Cohort 1: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 3.3%Cohort 2: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 1.2% NCT02155101 · Phase 3 · registry result, not featured evidence 22.2%Treatment-Experienced NCT01440569 · Phase 3 · registry result, not featured evidence 12.2%Treatment-Naive NCT01440569 · Phase 3 · registry result, not featured evidence 13.2%DRV/Rtv + 2NRTIs NCT01448707 · Phase 3 · registry result, not featured evidence · combination 13.1%DRV/Rtv MONO NCT01448707 · Phase 3 · registry result, not featured evidence 12.3%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 12.1%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 11.3% NCT01516970 · Phase 3 · registry result, not featured evidence 13.9%800/100 mg once daily NCT00524368 · Phase 3 · registry result, not featured evidence 16.2%600/100 mg twice daily NCT00524368 · Phase 3 · registry result, not featured evidence 18.9%800/100 mg once a day NCT00458302 · Phase 3 · registry result, not featured evidence 12% NCT00993148 · Phase 2 · registry result, not featured evidence · combination 0%800/100 mg NCT01391013 · Phase 2 · registry result, not featured evidence · monotherapy 0%Combination Therapy NCT01391013 · Phase 2 · registry result, not featured evidence · combination 0% NCT00915655 · Phase 2 · registry result, not featured evidence 4.8% NCT00919854 · Phase 2 · registry result, not featured evidence 13.4%RAL + DRV/RTV NCT00830804 · Phase 2 · registry result, not featured evidence · combination —RAL+DRV/RTV NCT00830804 · Phase 2 · registry result, not featured evidence · combination 0%Part A: SOF+EFV+ZDV/3TC (Cohort 2) NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination 8.3%Part A: SOF+EFV/FTC/TDF (Cohort 1) NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination 0%Part A: SOF+RAL+FTC/TDF (Cohort 5) NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination 0%Part A: SOF+RTV+ATV+FTC/TDF (Cohor NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination 0%Part A: SOF+RTV+DRV+FTC/TDF (Cohor NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination —Part B: SOF+PEG+RBV NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination | 80.4% NCT00144170 · Phase 3 · monotherapy · HIV · phase 3 show 1 more result83.7% NCT00054717 · Phase 3 · combination · HIV · phase 3 |
| Discontinued due to AEs | —a NCT01869634 · Phase 4 · registry result, not featured evidence show 34 more results—Darunavir/Ritonavir Alone NCT00630734 · Phase 4 · registry result, not featured evidence · monotherapy —Pravastatin + Darunavir/Ritonavir NCT00630734 · Phase 4 · registry result, not featured evidence · combination — NCT00543101 · Phase 4 · registry result, not featured evidence 0%Continued Treatment With DRV in Co NCT01281813 · Phase 3 · registry result, not featured evidence · combination 7.3%Continued Treatment With DRV in Co NCT01281813 · Phase 3 · registry result, not featured evidence · combination 0%Continued Treatment With DRV in Co NCT01281813 · Phase 3 · registry result, not featured evidence · combination —D/C/F/TAF: Extension Study NCT03227861 · Phase 3 · registry result, not featured evidence —D/C/F/TAF: Main Study NCT03227861 · Phase 3 · registry result, not featured evidence —Cohort 1: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination —Cohort 2: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination — NCT02155101 · Phase 3 · registry result, not featured evidence 0%Treatment-Experienced NCT01440569 · Phase 3 · registry result, not featured evidence 3%Treatment-Naive NCT01440569 · Phase 3 · registry result, not featured evidence 0.7%DRV/Rtv + 2NRTIs NCT01448707 · Phase 3 · registry result, not featured evidence · combination 2.2%DRV/Rtv MONO NCT01448707 · Phase 3 · registry result, not featured evidence 4.1%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 6.1%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 0.6% NCT01516970 · Phase 3 · registry result, not featured evidence 3.4%800/100 mg once daily NCT00524368 · Phase 3 · registry result, not featured evidence 4.1%600/100 mg twice daily NCT00524368 · Phase 3 · registry result, not featured evidence 11%800/100 mg once a day NCT00458302 · Phase 3 · registry result, not featured evidence — NCT00993148 · Phase 2 · registry result, not featured evidence · combination —800/100 mg NCT01391013 · Phase 2 · registry result, not featured evidence · monotherapy —Combination Therapy NCT01391013 · Phase 2 · registry result, not featured evidence · combination — NCT00915655 · Phase 2 · registry result, not featured evidence 4.8% NCT00919854 · Phase 2 · registry result, not featured evidence —RAL + DRV/RTV NCT00830804 · Phase 2 · registry result, not featured evidence · combination —RAL+DRV/RTV NCT00830804 · Phase 2 · registry result, not featured evidence · combination —Part A: SOF+EFV+ZDV/3TC (Cohort 2) NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination —Part A: SOF+EFV/FTC/TDF (Cohort 1) NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination —Part A: SOF+RAL+FTC/TDF (Cohort 5) NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination —Part A: SOF+RTV+ATV+FTC/TDF (Cohor NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination —Part A: SOF+RTV+DRV+FTC/TDF (Cohor NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination —Part B: SOF+PEG+RBV NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination | 19.2% NCT00144170 · Phase 3 · monotherapy · HIV · phase 3 show 1 more result22.4% NCT00054717 · Phase 3 · combination · HIV · phase 3 |
| Serious AEs | 0%a NCT01869634 · Phase 4 · registry result, not featured evidence show 34 more results0%Darunavir/Ritonavir Alone NCT00630734 · Phase 4 · registry result, not featured evidence · monotherapy 3.6%Pravastatin + Darunavir/Ritonavir NCT00630734 · Phase 4 · registry result, not featured evidence · combination 0% NCT00543101 · Phase 4 · registry result, not featured evidence 25%Continued Treatment With DRV in Co NCT01281813 · Phase 3 · registry result, not featured evidence · combination 19%Continued Treatment With DRV in Co NCT01281813 · Phase 3 · registry result, not featured evidence · combination 0%Continued Treatment With DRV in Co NCT01281813 · Phase 3 · registry result, not featured evidence · combination 5%D/C/F/TAF: Extension Study NCT03227861 · Phase 3 · registry result, not featured evidence 9.2%D/C/F/TAF: Main Study NCT03227861 · Phase 3 · registry result, not featured evidence 4.8%Cohort 1: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 10.1%Cohort 2: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 3.7% NCT02155101 · Phase 3 · registry result, not featured evidence 27.8%Treatment-Experienced NCT01440569 · Phase 3 · registry result, not featured evidence 15.3%Treatment-Naive NCT01440569 · Phase 3 · registry result, not featured evidence 10.3%DRV/Rtv + 2NRTIs NCT01448707 · Phase 3 · registry result, not featured evidence · combination 13.1%DRV/Rtv MONO NCT01448707 · Phase 3 · registry result, not featured evidence 15.1%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 18.2%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 0.6% NCT01516970 · Phase 3 · registry result, not featured evidence 5.4%800/100 mg once daily NCT00524368 · Phase 3 · registry result, not featured evidence 9.1%600/100 mg twice daily NCT00524368 · Phase 3 · registry result, not featured evidence 11%800/100 mg once a day NCT00458302 · Phase 3 · registry result, not featured evidence 0% NCT00993148 · Phase 2 · registry result, not featured evidence · combination 0%800/100 mg NCT01391013 · Phase 2 · registry result, not featured evidence · monotherapy 0%Combination Therapy NCT01391013 · Phase 2 · registry result, not featured evidence · combination 25% NCT00915655 · Phase 2 · registry result, not featured evidence 9.5% NCT00919854 · Phase 2 · registry result, not featured evidence —RAL + DRV/RTV NCT00830804 · Phase 2 · registry result, not featured evidence · combination 11.6%RAL+DRV/RTV NCT00830804 · Phase 2 · registry result, not featured evidence · combination 0%Part A: SOF+EFV+ZDV/3TC (Cohort 2) NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination 0%Part A: SOF+EFV/FTC/TDF (Cohort 1) NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination 0%Part A: SOF+RAL+FTC/TDF (Cohort 5) NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination 0%Part A: SOF+RTV+ATV+FTC/TDF (Cohor NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination 0%Part A: SOF+RTV+DRV+FTC/TDF (Cohor NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination 0%Part B: SOF+PEG+RBV NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination | 28.1% NCT00144170 · Phase 3 · monotherapy · HIV · phase 3 show 1 more result36.3% NCT00054717 · Phase 3 · combination · HIV · phase 3 |
| Most frequent reported AEs | a nausea/vomiting/dyspepsia/abdominal pain 38.7% diarrhea 25.8% headache 25.8% NCT00630734 · Phase 4 · registry result, not featured evidence · monotherapy show 31 more resultsdiarrhea 46.4% headache 21.4% muscle pain 10.7% NCT00630734 · Phase 4 · registry result, not featured evidence · combination abnormal liver function test 33.3% nasal congestion 25% bronchitis 16.7% NCT00543101 · Phase 4 · registry result, not featured evidence pregnancy 0% NCT01281813 · Phase 3 · registry result, not featured evidence · combination pregnancy 2.9% NCT01281813 · Phase 3 · registry result, not featured evidence · combination pregnancy 0% NCT01281813 · Phase 3 · registry result, not featured evidence · combination diarrhoea 6.3% vitamin d deficiency 6.3% pain in extremity 5% NCT03227861 · Phase 3 · registry result, not featured evidence diarrhoea 24.8% nausea 15.6% headache 9.2% NCT03227861 · Phase 3 · registry result, not featured evidence acute sinusitis 19% bronchitis 14.3% sinusitis 14.3% NCT01968551 · Phase 3 · registry result, not featured evidence · combination back pain 12.4% upper respiratory tract infection 11.2% bronchitis 6.7% NCT01968551 · Phase 3 · registry result, not featured evidence · combination acute hepatitis b 1.2% hypertension 1.2% pulmonary tb 1.2% NCT02155101 · Phase 3 · registry result, not featured evidence diarrhoea 44.4% nasopharyngitis 22.2% sinusitis 22.2% NCT01440569 · Phase 3 · registry result, not featured evidence diarrhoea 33.6% nausea 27.1% upper respiratory tract infection 23.7% NCT01440569 · Phase 3 · registry result, not featured evidence nasopharyngitis 8.1% diarrhoea 7.4% headache 6.6% NCT01448707 · Phase 3 · registry result, not featured evidence · combination diarrhoea 13.1% nasopharyngitis 11.7% back pain 7.3% NCT01448707 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 20.5% nasopharyngitis 19.2% bronchitis 13.7% NCT01363011 · Phase 3 · registry result, not featured evidence · combination diarrhoea 36.4% insomnia 21.2% headache 18.2% NCT01363011 · Phase 3 · registry result, not featured evidence · combination diarrhoea 28.3% nausea 15.1% fatigue 13.2% NCT01516970 · Phase 3 · registry result, not featured evidence 800/100 mg once daily diarrhoea 14.3% nausea 12.9% headache 6.8% NCT00524368 · Phase 3 · registry result, not featured evidence 600/100 mg twice daily diarrhoea 22.3% nausea 14.2% vomiting 8.4% NCT00524368 · Phase 3 · registry result, not featured evidence 800/100 mg once a day diarrhoea 20.5% hypercholesterolaemia 15% nasopharyngitis 11.8% NCT00458302 · Phase 3 · registry result, not featured evidence 800/100 mg blood cholesterol increased 26.7% low density lipoprotein increased 26.7% pyrexia 20% NCT01391013 · Phase 2 · registry result, not featured evidence · monotherapy diarrhoea 20% blood creatine phosphokinase increased 13.3% blood triglycerides increased 6.7% NCT01391013 · Phase 2 · registry result, not featured evidence · combination upper respiratory tract infection 28.6% cough 23.8% diarrhoea 23.8% NCT00919854 · Phase 2 · registry result, not featured evidence blood cholesterol 40.2% low density lipoprotein abnormal 30.4% aspartate aminotransferase increased 13.4% NCT00830804 · Phase 2 · registry result, not featured evidence · combination abdominal pain 0% agitation 0% anaemia 0% NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination agitation 8.3% body temperature decreased 8.3% chills 8.3% NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination dry mouth 14.3% haemorrhoids 14.3% abdominal pain 0% NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination abdominal pain 0% agitation 0% anaemia 0% NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination cough 14.3% fungal skin infection 14.3% nasal congestion 14.3% NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination anaemia 52.2% fatigue 34.8% hyperbilirubinaemia 17.4% NCT01565889 · Phase 1/2 · registry result, not featured evidence · combination | show 1 more result |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Darunavir
show 11 more results
show 9 more results
show 8 more results
show 3 more results
show 2 more results
show 1 more result
show 2 more results
show 7 more results
show 3 more results
show 1 more result
+ 36 further endpoints in the CSV export.
Tipranavir
show 58 more results
show 3 more results
show 3 more results
show 27 more results
show 1 more result
show 26 more results
show 14 more results
show 14 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Darunavir's landscape · Tipranavir's landscape